Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels

Br J Clin Pharmacol. 2022 Mar;88(3):1387-1391. doi: 10.1111/bcp.14953. Epub 2021 Jun 26.

Authors

Pinar Bakir Ekinci¹, Emre Kara¹, Ahmet Gorkem Er², Ahmet Cagkan Inkaya², Kutay Demirkan¹, Omrum Uzun²

Affiliations

¹ Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
² Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

No abstract available

Publication types

Letter

MeSH terms

Antifungal Agents / adverse effects
COVID-19*
Humans
Pulmonary Aspergillosis* / drug therapy
SARS-CoV-2
Voriconazole / adverse effects

Substances

Antifungal Agents
Voriconazole